Cutting off the power: inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling?
暂无分享,去创建一个
W. Junger | C. Ledderose | Richard Seist | Jingping Zhang | T. Woehrle | Y. Bao | S. Ledderose | Katharina Strasser | Stephan Ledderose
[1] Leslie L Robison,et al. Acute lymphoblastic leukaemia , 2018, Radiopaedia.org.
[2] M. Haigis,et al. Mitochondria and Cancer , 2016, Cell.
[3] N. Shapiro,et al. Mitochondrial Dysfunction, Depleted Purinergic Signaling, and Defective T Cell Vigilance and Immune Defense. , 2016, The Journal of infectious diseases.
[4] W. Junger,et al. mTOR and differential activation of mitochondria orchestrate neutrophil chemotaxis , 2015, The Journal of cell biology.
[5] O. Abdel-Wahab,et al. Hairy cell leukemia: update and current therapeutic approach , 2015, Current opinion in hematology.
[6] D Andrews,et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.
[7] W. Junger,et al. Mitochondria Regulate Neutrophil Activation by Generating ATP for Autocrine Purinergic Signaling* , 2014, The Journal of Biological Chemistry.
[8] W. Junger,et al. Plasma ATP is Required for Neutrophil Activation in a Mouse Sepsis Model , 2014, Shock.
[9] N. Shapiro,et al. Mitochondria Are Gate-keepers of T Cell Function by Producing the ATP That Drives Purinergic Signaling* , 2014, The Journal of Biological Chemistry.
[10] D. Sabatini,et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides , 2014, Nature.
[11] T. Robak,et al. Older and new purine nucleoside analogs for patients with acute leukemias. , 2013, Cancer treatment reviews.
[12] L. Antonioli,et al. Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.
[13] F. Di Virgilio,et al. Purinergic signalling and cancer , 2013, Purinergic Signalling.
[14] A. Ojida,et al. Organelle-localizable fluorescent chemosensors for site-specific multicolor imaging of nucleoside polyphosphate dynamics in living cells. , 2012, Journal of the American Chemical Society.
[15] N. Sträter,et al. Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.
[16] M. Smyth,et al. CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.
[17] S. Devesa,et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.
[18] W. Junger,et al. Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.
[19] P. Insel,et al. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. , 2010, Blood.
[20] B. Fredholm,et al. The birth and postnatal development of purinergic signalling , 2010, Acta physiologica.
[21] P. Insel,et al. Autocrine regulation of T‐cell activation by ATP release and P2X7 receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[23] F. Di Virgilio,et al. P2X7: a growth-promoting receptor—implications for cancer , 2009, Purinergic Signalling Purinergic Signalling.
[24] C. Pui. T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. , 2009, Cancer cell.
[25] J. Buer,et al. Purinergic Control of T Cell Activation by ATP Released Through Pannexin-1 Hemichannels , 2008, Science Signaling.
[26] F. Di Virgilio,et al. Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase , 2008, PloS one.
[27] P. Insel,et al. HYPERTONIC STRESS REGULATES T-CELL FUNCTION BY THE OPPOSING ACTIONS OF EXTRACELLULAR ADENOSINE TRIPHOSPHATE AND ADENOSINE , 2007, Shock.
[28] M. Sporn,et al. The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.
[29] A. Ohta,et al. A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.
[30] S. Jalkanen,et al. The detection of micromolar pericellular ATP pool on lymphocyte surface by using lymphoid ecto-adenylate kinase as intrinsic ATP sensor. , 2006, Molecular biology of the cell.
[31] G. Burnstock,et al. P2 receptors and cancer. , 2006, Trends in pharmacological sciences.
[32] Xiao-tong Ma,et al. Expression of P2X7 in human hematopoietic cell lines and leukemia patients. , 2004, Leukemia research.
[33] M. Poot,et al. Efficacy of MitoTracker Green™ and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[34] M. Guppy,et al. Cancer metabolism: facts, fantasy, and fiction. , 2004, Biochemical and biophysical research communications.
[35] F. Di Virgilio,et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. , 2002, Blood.
[36] F. Meyers,et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Steinkamp,et al. Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs. , 2000, Cytometry.
[38] F. Di Virgilio,et al. Increased Proliferation Rate of Lymphoid Cells Transfected with the P2X7 ATP Receptor* , 1999, The Journal of Biological Chemistry.
[39] N. Sriranganathan,et al. A dye-based lymphocyte proliferation assay that permits multiple immunological analyses: mRNA, cytogenetic, apoptosis, and immunophenotyping studies. , 1997, Journal of immunological methods.
[40] M. R. Cooper,et al. Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.
[41] O. Sartor,et al. Acute renal toxicity associated with suramin in the treatment of prostate cancer , 1994, Cancer.
[42] J. Wilting,et al. Recent research on the biological activity of suramin. , 1993, Pharmacological reviews.
[43] C. Taylor,et al. Effects of suramin on in vitro growth of fresh human tumors. , 1992, Journal of the National Cancer Institute.
[44] W. Linehan,et al. Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.
[45] M. Sitkovsky,et al. Extracellular ATP in T-lymphocyte activation: possible role in effector functions. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Pollak,et al. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. , 1990, Journal of the National Cancer Institute.
[47] J. Fitchen,et al. Purine metabolism as a target for leukemia chemotherapy. , 1989, Blood reviews.
[48] G. Reaman,et al. Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. , 1981, Cancer research.
[49] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[50] S. Weinberg,et al. Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.
[51] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[52] Geoffrey Burnstock,et al. Purinergic signalling , 2012, Acta physiologica.
[53] G. Giaccone,et al. Effects of suramin on human lung cancer cell lines. , 1995, European Journal of Cancer.
[54] M. Hosang. Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.
[55] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.